Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 Debt-to-EBITDA is 1.22 as of Jun. 2026, which is 713% above its 10-year median of 0.15. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $44.37 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 56.96% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Xvivo Perfusion AB's Debt-to-EBITDA or its related term are showing as below:
XVIPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.27 Med: 0.15 Max: 1.11
Current: 1.09
During the past 13 years, the highest Debt-to-EBITDA Ratio of Xvivo Perfusion AB was 1.11. The lowest was -0.27. And the median was 0.15.
XVIPF's Debt-to-EBITDA is ranked better than 56.96% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs XVIPF: 1.09
Xvivo Perfusion AB (OTCPK:XVIPF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Xvivo Perfusion AB Debt-to-EBITDA Related Terms
Xvivo Perfusion AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Xvivo Perfusion AB (XVIPF) has a Debt-to-EBITDA of 1.22 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Xvivo Perfusion AB. This is 713% above median its historical median of 0.15. According to the industry distribution chart, Xvivo Perfusion AB ranks #201 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 43%.
Is Xvivo Perfusion AB's Debt-to-EBITDA too high?
Xvivo Perfusion AB's current Debt-to-EBITDA of 1.22 is 713% above median its 10-year median of 0.15. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Xvivo Perfusion AB's value of 1.22 is 23.8% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #201 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #201 out of 467 companies for Debt-to-EBITDA. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median Debt-to-EBITDA is 1.60. Xvivo Perfusion AB's value of 1.22 is 23.8% below this benchmark. While the company's 10-year median is 0.15 vs. the industry median of 1.60, Xvivo Perfusion AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Debt-to-EBITDA of 1.22 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Xvivo Perfusion AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Debt-to-EBITDA is 1.22, which is 713% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.37, compared to a current price of $24.50 — trading 44.8% below its estimated fair value. The current Debt-to-EBITDA is 1.22, which is 713% above median its 10-year median of 0.15 and 23.8% below the Medical Devices & Instruments industry median of 1.60. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Debt-to-EBITDA is 1.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $24.50 is trading 44.8% below its estimated GF Value™ of $44.37.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Debt-to-EBITDA: 1.22 (713% above median its 10-year median of 0.15)
GF Value™: $44.37 vs. price of $24.50 (44.8% below fair value)
Industry Position: 23.8% below the Medical Devices & Instruments median (#201 of 467)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
